Nicolas Poirier

Nicolas Poirier

Company: OSE Immunotherapeutics

Job title: Chief Scientific Officer


BiCKI: An Optimized Anti-PD1 Bispecific Platform In Particular For Immunocytokine Such As With IL-7. 5:15 pm

The BiCKI monovalent anti-PD1 platform has been optimized for manufacturing and pharmacokinetics of innovative bispecific fusion proteins Key roles of the valency and affinity of fused cytokines Significant preclinical efficacy of anti-PD1/IL-7 bispecific in syngeneic immunocompetent or humanized mice modelsRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.